Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - GENZYME CORP | b84252exv99w1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED):
January 11, 2011
January 11, 2011
GENZYME CORPORATION
(Exact name of registrant as specified in its charter)
| Massachusetts | 0-14680 | 06-1047163 | ||
| (State or other jurisdiction of incorporation or organization) |
(Commission file number) | (IRS employer identification number) |
500 Kendall Street, Cambridge, Massachusetts 02142
(Address of Principal Executive Offices) (Zip Code)
(Address of Principal Executive Offices) (Zip Code)
Registrant’s telephone number, including area code:
(617) 252-7500
(617) 252-7500
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.02 Results of Operations and Financial Condition.
On January 11, 2011, Genzyme Corporation issued a press release containing certain information
related to its results of operations and financial condition for the three and twelve month periods
ended December 31, 2010. A copy of the press release is furnished as Exhibit 99.1 to this Form
8-K.
Item 9.01 Financial Statements and Exhibits.
| (d) | Exhibits |
| 99.1 | Press Release of Genzyme Corporation dated January 11, 2011. |
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: January 11, 2011 | GENZYME CORPORATION |
|||
| By: | /s/ Thomas J. DesRosier | |||
| Name: | Thomas J. DesRosier | |||
| Title: | Senior Vice President, General Counsel and Chief Legal Officer |
|||
2